BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23294549)

  • 21. Is contraceptive self-injection cost-effective compared to contraceptive injections from facility-based health workers? Evidence from Uganda.
    Di Giorgio L; Mvundura M; Tumusiime J; Morozoff C; Cover J; Drake JK
    Contraception; 2018 Nov; 98(5):396-404. PubMed ID: 30098940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi.
    Burke HM; Chen M; Packer C; Fuchs R; Ngwira B
    J Adolesc Health; 2020 Nov; 67(5):700-707. PubMed ID: 32389457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs of administering injectable contraceptives through health workers and self-injection: evidence from Burkina Faso, Uganda, and Senegal.
    Di Giorgio L; Mvundura M; Tumusiime J; Namagembe A; Ba A; Belemsaga-Yugbare D; Morozoff C; Brouwer E; Ndour M; Drake JK
    Contraception; 2018 Nov; 98(5):389-395. PubMed ID: 29859148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient's experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19.
    Smith TJ; Urdanigo TK; Shroff N; Rubin SE
    Contraception; 2023 Jul; 123():110008. PubMed ID: 36931548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries.
    Stout A; Wood S; Barigye G; Kaboré A; Siddo D; Ndione I
    Glob Health Sci Pract; 2018 Mar; 6(1):55-72. PubMed ID: 29602866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL.
    Westhoff C; Jain JK; Milsom I; Ray A
    Contraception; 2007 Apr; 75(4):261-7. PubMed ID: 17362703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study.
    Cover J; Ba M; Lim J; Drake JK; Daff BM
    Contraception; 2017 Sep; 96(3):203-210. PubMed ID: 28673645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Would you be interested in DMPA-SC? An implementation project in two urban primary care clinics.
    Miles C; Ennamuri D; Yeh J; Shih G
    Contraception; 2022 Aug; 112():116-119. PubMed ID: 35123982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.
    Burke HM; Mueller MP; Perry B; Packer C; Bufumbo L; Mbengue D; Mall I; Daff BM; Mbonye AK
    Contraception; 2014 May; 89(5):361-7. PubMed ID: 24631328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results.
    Okegbe T; Affo J; Djihoun F; Zannou A; Hounyo O; Ahounou G; Bangbola KA; Harris N
    Glob Health Sci Pract; 2019 Jun; 7(2):228-239. PubMed ID: 31171559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adolescent and covert family planning users' experiences self-injecting contraception in Uganda and Malawi: implications for waste disposal of subcutaneous depot medroxyprogesterone acetate.
    Burke HM; Packer C; Wando L; Wandiembe SP; Muwereza N; Pradhan S; Zingani A; Ngwira B
    Reprod Health; 2020 Aug; 17(1):117. PubMed ID: 32746860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC).
    Kohn JE; Berlan ED; Tang JH; Beasley A
    Contraception; 2022 Aug; 112():11-13. PubMed ID: 35378085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda.
    Odwe G; Gray K; Kyarimpa A; Obare F; Nagendi G
    Glob Health Sci Pract; 2018 Dec; 6(4):711-722. PubMed ID: 30429201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate.
    Curtis KM; Nguyen A; Reeves JA; Clark EA; Folger SG; Whiteman MK
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(20):739-743. PubMed ID: 34014910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
    Nanda K; Callahan R; Taylor D; Wang M; Agot K; Jenkins D; Van Damme L; Dorflinger L;
    Contraception; 2016 Jul; 94(1):40-7. PubMed ID: 26972780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient satisfaction of depot medroxyprogesterone acetate (dmpa-sc) injection as contraceptive.
    Chaudhri R; Rizvi F; Afzal M
    J Pak Med Assoc; 2010 Jul; 60(7):536-40. PubMed ID: 20578601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An observational study to test the acceptability and feasibility of using medical and nursing students to instruct clients in DMPA-SC self-injection at the community level in Kinshasa.
    Bertrand JT; Bidashimwa D; Makani PB; Hernandez JH; Akilimali P; Binanga A
    Contraception; 2018 Nov; 98(5):411-417. PubMed ID: 30120925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review.
    Aderoba AK; Steyn PS; Kiarie JN
    Syst Rev; 2023 Jul; 12(1):114. PubMed ID: 37403147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg.
    Arias RD; Jain JK; Brucker C; Ross D; Ray A
    Contraception; 2006 Sep; 74(3):234-8. PubMed ID: 16904417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
    Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.